This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.

 

This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Speaker - Martin Lange
Martin
Lange
Novo Nordisk A/S, Copenhagen, Denmark

Martin Lange is executive vice president for Development at Novo Nordisk A/S, in Copenhagen, Denmark. He joined Novo Nordisk in 2002, working with growth hormone, GLP-1 and oral anti-diabetics as first operationally and subsequently medically responsible for several projects within Global Development.

 

Martin Lange worked two years in Novo Nordisk Inc., USA, from 2006-2008 in the Medical Department as senior medical director. In 2008, Martin Lange moved back to Denmark as vice president, Medical & Science liraglutide during the submission and approval phase, transferring in 2010 upon US approval of Victoza® to insulin degludec in a similar position.

 

From 2013 to 2017, he served as corporate project vice president for Insulin & Diabetes Outcomes and subsequently Insulin & Devices, being responsible for the development and approval of the Novo Nordisk insulin portfolio. In January 2018, he was appointed senior vice president for Global Development, assuming the overall clinical development responsibilities of the Novo Nordisk pipeline. In March 2021, Martin Lange was appointed executive vice president for Development.

 

Martin Lange is a doctor of medicine from the University of Copenhagen, where he also obtained a PhD in endocrinology.

properties.alt

Filip K. Knop

Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen; Steno Diabetes Center, Copenhagen, Denmark


Professor Filip K. Knop is Professor of Endocrinology and Director at the Center for Clinical Metabolic Research at Gentofte Hospital, University of Copenhagen, and Consultant Endocrinologist at Steno Diabetes Center, Copenhagen, Denmark. 

 

Professor Knop has been involved in diabetes, obesity and metabolic research since his fellowship at The Distinguished Gifford Laboratories for Diabetes Research, University of Texas, Southwestern Medical Center in Dallas, TX, USA in 1999/2000. He earned his MD in 2002 and his PhD in medical sciences in 2007 (supervised by Jens J. Holst) from University of Copenhagen, Denmark. 

 

Professor Knop’s research centres on human metabolism, the pathophysiology of obesity and related disorders including type 2 diabetes and non-alcoholic fatty liver disease, regulation of appetite and food intake, and the therapeutic potential of the factors involved in these processes.

 

The Knop laboratory has reported several novel findings describing the integrative role of the gut and the liver in human (patho)physiology. Professor Knop has authored more than 460 peer-reviewed scientific publications and has received multiple honours for his research. He was named ‘Rising star’ by the EASD in 2010, awarded the DPLU/LUDC Nordic Prize for an Outstanding Young Diabetes Investigator in 2011, Johan Quentin and Wife’s Prize for Outstanding Research in 2014, The Capital Region of Denmark’s Global Excellence Prize in 2014, The Thomsen Prize in 2015, The Niels Schwartz Sørensen Prize in 2017, The Odd Fellowship’s Research Prize in 2017, the European Journal of Endocrinology Prize 2018, and EASD’s Minkowski Prize 2019. 


Read full bio
properties.alt

Francesco Cosentino

Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden


Prof. Francesco Cosentino is Professor of Cardiology and Chair of Cardiovascular Medicine at the Karolinska Institute and Karolinska University Hospital in Stockholm, Sweden.

 

He earned his medical degree and completed his postgraduate training in internal medicine and cardiovascular disease at the University of Rome, Italy. In 1991 he moved to the Mayo Clinic & Foundation, Rochester, MN, USA for a cardiovascular fellowship. During his stay at the Mayo Clinic & Foundation, he fulfilled all the requirements for a PhD in biomedical sciences – cardiovascular pharmacology. In 1995, Prof. Cosentino joined the Cardiovascular Division at the University Hospital of Bern, Switzerland. Two years later, he moved to the Division of Cardiology of Zurich University Hospital as a lecturer and then Titular Professor of Cardiology. In 2006, he was appointed Associate Professor of Cardiology at the Sapienza University of Rome, Italy. He has been full Professor of Cardiology at the Karolinska Institute and Karolinska University Hospital in Stockholm since 2013.

 

Prof. Cosentino is the recipient of grants and prizes from national and international institutions, research councils and private foundations. He is the lead author of more than 250 original articles published in top-ranking, peer-reviewed journals. Prof. Cosentino is a member of the European Society of Cardiology (ESC) Board and Chair of ESC Advocacy Committee. He is Deputy Editor of the European Heart Journal and Consulting Editor of Cardiovascular Research Journal. He has been Chairman of the 2019 ESC Guidelines on diabetes, pre-diabetes and cardiovascular disease and in 2020–2022 Vice President of the ESC.


Read full bio
properties.alt

Kamlesh Khunti

Diabetes Research Centre,  University of Leicester, Leicester, UK


Professor Kamlesh Khunti is Professor of Primary Care Diabetes and Vascular Medicine at the University of Leicester, UK. He is Director of Leicester Diabetes Centre, Director of the UK National Institute for Health Research (NIHR) in Applied Research Collaborations (ARC) East Midlands, Director of the Centre for Ethnic Health Research and Director of the Real-World Evidence Unit.

 

Professor Khunti leads a programme of work on cardiometabolic diseases and multimorbidity. He was recently appointed as Director of the first NIHR Global Health Research Centre for Multiple Long-Term Conditions and Co-lead for the Multiple Long-Term Conditions Cross-NIHR Collaboration. He is the national NIHR ARC Lead for Multimorbidity and leads the national training programme for multimorbidity. Professor Khunti led a programme of work during the COVID-19 pandemic and is a member of UK government’s Scientific Advisory Group for Emergencies (SAGE) and Chair of the SAGE Ethnicity subgroup.

 

Professor Khunti has published over 1,200 peer-reviewed articles. He is Chair of the American Diabetes Association’s Overcoming Therapeutic Inertia initiative and is currently a member of the KDIGO Diabetes and CKD Guidelines Work Group and a member of the ADA Standards of Care in Diabetes Professional Practice Committee. He has won numerous awards in the UK and internationally and was awarded the Commander of the Order of the British Empire (CBE) in the 2022 New Year Honours List for services to health.


Read full bio
properties.alt

Kees Hovingh

Novo Nordisk A/S, Copenhagen, Denmark


Kees Hovingh is Senior Medical Officer, originally in the Global CMO, and now GMA at Novo Nordisk in Copenhagen, Denmark since 2019. In this role his responsibilities include defining and driving the R&D CVD strategy to address clinical needs for individuals living with obesity, cardiovascular disease, diabetes, and chronic kidney disease. He is involved in the evaluation of the clinical value of products and services at different stages of development, ranging from preclinical idea generation to leveraging the clinical value of marketed products. Kees is a member of a number of clinical trial steering commitees including ZEUS, SELECT, SOUL, Step-HF and the ATTR-phase 2 trial.

 

Kees received his medical degree in 2000, his PhD in 2005 and his MBA degree in 2016 from the University of Groningen. He is a full professor, internist and vascular medicine specialist at the Department of Vascular Medicine at the University Medical Center Amsterdam (UMCA), the Netherlands. Kees was co-chair of the department of internal medicine at the UMCA in 2016-2019 and in his role as head of the clinical trial unit (2012-2019) he has been involved in a large number of clinical trials, mainly focused on novel therapies to address dyslipidemia, thrombosis and hemophilia. His research focuses on genetics and molecular biology in CVD, and he did a post-doctoral fellowship at Harvard Genetics in Boston USA. Kees co-authored over 300 publications (Scholar H index: 91) and was named by Thomsen-Reuters in 2019 as the top1% most cited researchers.


Read full bio
properties.alt

Michael Nauck

Katholisches Klinikum Bochum gGmbH, St. Josef-Hospital, Medical Department I, Ruhr-University, Bochum, Germany


Professor Nauck has a particular research interest in the role of gastrointestinal peptide hormones (incretins: glucose-dependent insulinotropic polypeptide, GIP, and glucagon-like peptide-1, GLP-1) in the physiological regulation of metabolism and in the pathophysiology of type 2 diabetes. He has contributed pivotal studies proving a therapeutic potential of GLP-1 in type 2 diabetes, and has contributed to the development of incretin-based glucose-lowering medications such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4. Additional areas of interest include spontaneous hypoglycaemia (insulinomas), pancreas transplantation, cardiovascular complications of type 2 diabetes, and the modification of cardiovascular risk in type 2-diabetic patients with glucose-lowering pharmacotherapy.

 

Professor Nauck’s scientific contributions have been honoured with several awards, including the Ferdinand-Bertram Award (1993), the Werner-Creutzfeldt Award (2007) and the Paul Langerhans Medal (2012) from the German Diabetes Association, and the Claude Bernard Medal from the European Association for the Study of Diabetes (2022).

 

Professor Nauck has served as reviewer for many major diabetes journals and has published more than 250 original articles and 140 reviews and book chapters. His publications have been quoted more than 70,000 times, his “H-index” is 109, and he has been a “highly cited researcher” (among the top 1%) in 2019, 2021, and 2022(Web of Knowledge). Professor Nauck is member of a number of professional societies, including the German, European, and American Diabetes Associations, and the International Diabetes Federation.


Read full bio